MA26882A1 - COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE - Google Patents

COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE

Info

Publication number
MA26882A1
MA26882A1 MA26810A MA26810A MA26882A1 MA 26882 A1 MA26882 A1 MA 26882A1 MA 26810 A MA26810 A MA 26810A MA 26810 A MA26810 A MA 26810A MA 26882 A1 MA26882 A1 MA 26882A1
Authority
MA
Morocco
Prior art keywords
phosphorylase
glycogen
inhibitors
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
MA26810A
Other languages
English (en)
Inventor
Jay Hoover Dennis
Thomas Friesen Dwayne
Alan Lorenz Douglas
Mysore Shanker Ravi
Alan Schriver Nightingal James
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26882A1 publication Critical patent/MA26882A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MA26810A 2000-03-16 2002-09-11 COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE MA26882A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
MA26882A1 true MA26882A1 (fr) 2004-12-20

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26810A MA26882A1 (fr) 2000-03-16 2002-09-11 COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE

Country Status (32)

Country Link
US (1) US20010053778A1 (fr)
EP (1) EP1263414A1 (fr)
JP (1) JP2003526654A (fr)
KR (1) KR20020081445A (fr)
CN (1) CN1418089A (fr)
AP (1) AP2002002621A0 (fr)
AR (1) AR027656A1 (fr)
AU (1) AU2001242669A1 (fr)
BG (1) BG107037A (fr)
BR (1) BR0109189A (fr)
CA (1) CA2403241A1 (fr)
CO (1) CO5280087A1 (fr)
CZ (1) CZ20022955A3 (fr)
EA (1) EA200200858A1 (fr)
EE (1) EE200200530A (fr)
HU (1) HUP0204583A2 (fr)
IL (1) IL151320A0 (fr)
IS (1) IS6508A (fr)
MA (1) MA26882A1 (fr)
MX (1) MXPA02009097A (fr)
NO (1) NO20024386L (fr)
OA (1) OA12232A (fr)
PA (1) PA8513601A1 (fr)
PE (1) PE20011184A1 (fr)
PL (1) PL360780A1 (fr)
SK (1) SK12622002A3 (fr)
SV (1) SV2002000343A (fr)
TN (1) TNSN01040A1 (fr)
TR (1) TR200202184T2 (fr)
WO (1) WO2001068055A1 (fr)
YU (1) YU67202A (fr)
ZA (1) ZA200207290B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1402629A (zh) * 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2002070478A1 (fr) 2001-03-06 2002-09-12 Astrazeneca Ab Dérivés indolone capable de dégrader des vaisseaux
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
OA12625A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
CA2450748A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
DE602005023965D1 (de) 2004-03-08 2010-11-18 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
MX374548B (es) 2012-08-24 2025-03-06 Dow Global Technologies Llc Eteres de celulosa esterificados novedosos de alto peso molecular y homogeneidad.
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
WO2015009566A1 (fr) * 2013-07-19 2015-01-22 Siga Technologies, Inc. Préparation de tecovirimat amorphe
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations
US20250241586A1 (en) * 2024-01-04 2025-07-31 Debasish Banerjee Bioavailability and bioequivalence through intrinsic activity and KD measurements, in vivo, in humans

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
BG107037A (bg) 2003-04-30
EE200200530A (et) 2004-04-15
US20010053778A1 (en) 2001-12-20
IS6508A (is) 2002-08-16
CA2403241A1 (fr) 2001-09-20
HUP0204583A2 (hu) 2003-04-28
EA200200858A1 (ru) 2003-02-27
PE20011184A1 (es) 2001-11-15
PA8513601A1 (es) 2004-08-31
YU67202A (sh) 2006-01-16
TR200202184T2 (tr) 2003-01-21
PL360780A1 (en) 2004-09-20
CN1418089A (zh) 2003-05-14
NO20024386L (no) 2002-11-13
AU2001242669A1 (en) 2001-09-24
CZ20022955A3 (cs) 2003-09-17
MXPA02009097A (es) 2003-03-12
AP2002002621A0 (en) 2002-09-30
AR027656A1 (es) 2003-04-09
WO2001068055A1 (fr) 2001-09-20
SK12622002A3 (sk) 2004-02-03
EP1263414A1 (fr) 2002-12-11
OA12232A (en) 2006-05-10
TNSN01040A1 (fr) 2005-11-10
JP2003526654A (ja) 2003-09-09
NO20024386D0 (no) 2002-09-13
IL151320A0 (en) 2003-04-10
KR20020081445A (ko) 2002-10-26
CO5280087A1 (es) 2003-05-30
SV2002000343A (es) 2002-07-03
ZA200207290B (en) 2003-09-11
BR0109189A (pt) 2003-05-27

Similar Documents

Publication Publication Date Title
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
DZ3391A1 (fr) Compositions pharmaceutiques d'inhibiteurs de proteine de transfert d'ester de cholesteryle
ATE263558T1 (de) Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
HUP0400206A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
HUP0301472A3 (en) Carbamate caspase inhibitors and uses thereof and pharmaceutical compositions containing them
HUP0103575A2 (hu) Kaszpáz inhibitorok peptidek, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0302435A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and pharmaceutical compositions containing them
EE05585B1 (et) Indasoolihendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ning nende kasutamine
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
HUP0201463A3 (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect and their use
EP1080226A4 (fr) Compostions et methodes pour l'administration topique d'oligonucleotides
HUP0302991A3 (en) Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds
MA26618A1 (fr) Composes et compositions pharmaceutiques pour le traitement du paludisme
EP1443905A4 (fr) Compositions pour therapie genique orale et procedes d'utilisation associes
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
DE60225014D1 (de) Pharmazeutische zusammensetzungen von amlodipin und atorvastatin
EP1423399A4 (fr) Chelateurs d'hydroxypyridonate et d'hydroxypyrimidinone
EE05020B1 (et) Glburiidi ravimkoostis
EE200200271A (et) Ravimkombinatsioonid ning nende kasutamine
NO20034778L (no) Farmasöytiske sammensetninger for oral og topisk anvendelse
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
EE04838B1 (et) Interleukiin-18 inhibiitorite kasutamine kasvaja metastaaside pärssimiseks sobivate ravimite valmistamiseks ning selliseid inhibiitoreid sisaldav farmatseutiline kompositsioon
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions